Literature DB >> 30214861

Exercise capacity in asymptomatic patients with significant primary mitral regurgitation: independent effect of global longitudinal left ventricular strain.

Amgad Mentias1, Alaa Alashi1, Peyman Naji1, A Marc Gillinov1, L Leonardo Rodriguez1, Tomislav Mihaljevic1, Rakesh M Suri1, Richard A Grimm1, Lars G Svensson1, Brian P Griffin1, Milind Y Desai1.   

Abstract

BACKGROUND: Despite preserved left ventricular ejection fraction (LVEF), patients with significant primary mitral regurgitation (MR) often have reduced exercise capacity. In asymptomatic patients with ≥3+ primary MR undergoing rest-stress echocardiography (RSE), we sought to evaluate the incremental impact of left ventricular global longitudinal strain (LV-GLS) on exercise capacity.
METHODS: A total of 660 asymptomatic patients with ≥3+ primary MR, non-dilated LV and LVEF ≥60% (mean age, 57±14 years, 66% men, body mass index or BMI 25±4 kg/m2) who underwent RSE at our center between 2001 and 2013 were included. Standard RSE data were obtained. Average resting LV-GLS was measured using Velocity Vector Imaging.
RESULTS: Mean mitral effective regurgitant orifice, resting right ventricular systolic pressure (RVSP) and LV-GLS were 0.45±0.2 cm2, 31±12 mmHg and -21.7%±2%, respectively; 28% had flail mitral leaflet. Mean metabolic equivalents (METs) and post-stress RVSP were 9.9±3, and 46±15 mmHg; 28% achieved <100% age-gender predicted METs. No patient had ischemia or significant arrhythmias. On logistic regression, resting LV-GLS [odds ratio (OR), 1.40, 95% confidence interval (CI): 1.21-1.55, BMI (OR, 1.11, 95% CI: 1.06-1.17)] and resting RVSP 1.22 (1.02-1.49) were independent predictors of exercise capacity. Area under the curve for association between 100% age-gender predicted METs and various factors were as follows: (I) BMI (0.60, 95% CI: 0.55-0.65, P<0.001); (II) resting RVSP (0.57, 95% CI: 0.52-0.62, P=0.006) and LV-GLS (0.66, 95% CI: 0.61-0.70, P<0.001).
CONCLUSIONS: In asymptomatic patients with ≥3+ primary MR, non-dilated LV and preserved LVEF, LV-GLS is independently associated with exercise capacity, beyond known predictors.

Entities:  

Keywords:  Mitral regurgitation (MR); exercise capacity; global LV longitudinal strain

Year:  2018        PMID: 30214861      PMCID: PMC6129839          DOI: 10.21037/cdt.2018.05.03

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  29 in total

1.  Prediction of left ventricular ejection fraction 6 months after surgical correction of organic mitral regurgitation: the value of exercise echocardiography and deformation imaging.

Authors:  Erwan Donal; Sophie Mascle; Anne Brunet; Christophe Thebault; Herve Corbineau; Marcel Laurent; Alain Leguerrier; Philippe Mabo
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-04-14       Impact factor: 6.875

2.  American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography.

Authors:  Patricia A Pellikka; Sherif F Nagueh; Abdou A Elhendy; Cathryn A Kuehl; Stephen G Sawada
Journal:  J Am Soc Echocardiogr       Date:  2007-09       Impact factor: 5.251

3.  Importance of left ventricular longitudinal function and functional reserve in patients with degenerative mitral regurgitation: assessment by two-dimensional speckle tracking.

Authors:  Patrizio Lancellotti; Bernard Cosyns; Dimitris Zacharakis; Emilio Attena; Guy Van Camp; Olivier Gach; Marc Radermecker; Luc A Piérard
Journal:  J Am Soc Echocardiogr       Date:  2008-12       Impact factor: 5.251

4.  Left ventricular contractile reserve in asymptomatic primary mitral regurgitation.

Authors:  Julien Magne; Haifa Mahjoub; Raluca Dulgheru; Philippe Pibarot; Luc A Pierard; Patrizio Lancellotti
Journal:  Eur Heart J       Date:  2013-09-07       Impact factor: 29.983

5.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas
Journal:  Circulation       Date:  2014-03-03       Impact factor: 29.690

6.  Left and right ventricular strain and strain rate measurement in normal adults using velocity vector imaging: an assessment of reference values and intersystem agreement.

Authors:  Nowell M Fine; Aijaz A Shah; Il-Yong Han; Yang Yu; Ju-Feng Hsiao; Yuki Koshino; Hayder K Saleh; Fletcher A Miller; Jae K Oh; Patricia A Pellikka; Hector R Villarraga
Journal:  Int J Cardiovasc Imaging       Date:  2012-09-14       Impact factor: 2.357

7.  Impact of left ventricular diastolic function on exercise capacity in patients with chronic mitral regurgitation: an exercise echocardiography study.

Authors:  Hyung-Kwan Kim; Yong-Jin Kim; Joong-Wha Chung; Dae-Won Sohn; Young-Bae Park; Yun-Shik Choi
Journal:  Clin Cardiol       Date:  2004-11       Impact factor: 2.882

8.  Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation.

Authors:  Rahal Yusoff; Nigel Clayton; Brian Keevil; Julie Morris; Simon Ray
Journal:  Am J Cardiol       Date:  2006-03-29       Impact factor: 2.778

9.  Head-to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors: The EACVI/ASE Inter-Vendor Comparison Study.

Authors:  Konstantinos E Farsalinos; Ana M Daraban; Serkan Ünlü; James D Thomas; Luigi P Badano; Jens-Uwe Voigt
Journal:  J Am Soc Echocardiogr       Date:  2015-07-23       Impact factor: 5.251

10.  Exercise-induced changes in degenerative mitral regurgitation.

Authors:  Julien Magne; Patrizio Lancellotti; Luc A Piérard
Journal:  J Am Coll Cardiol       Date:  2010-07-20       Impact factor: 24.094

View more
  1 in total

Review 1.  Clinical Applications of Echo Strain Imaging: a Current Appraisal.

Authors:  Agostina M Fava; Dane Meredith; Milind Y Desai
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-08-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.